Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | ADG106 + ADG116 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ADG106 | ADG-106|ADG 106 | TNFRSF9 Antibody 30 | ADG106 is an activating monoclonal antibody to TNFRSF9 (CD137) (NCI Drug Dictionary). | |
ADG116 | ADG-116|ADG 116 | CTLA4 Antibody 29 Immune Checkpoint Inhibitor 147 | ADG116 is a human monoclonal antagonistic antibody against CTLA4, which may stimulate anti-tumor immune response (PMID: 31694708). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04501276 | Phase I | ADG116 ADG106 + ADG116 ADG116 + unspecified PD-1 antibody | A Phase 1b Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients | Active, not recruiting | USA | AUS | 0 |